CANY
PCRX icon

Caxton Associates (New York)’s Pacira BioSciences PCRX Stock Holding History

Caxton Associates (New York)’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-34,200
Closed -$515K – 631
2024
Q3 		$515K Buy
+34,200
New +$585K 0.02% 359
2020
Q3 		– Sell
-4,866
Closed -$255K – 464
2020
Q2 		$255K Buy
+4,866
New +$203K 0.02% 308

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Caxton Associates (New York)'s PCRX Position: Q4 2024 in Review

Caxton Associates (New York) sold out of Pacira BioSciences (PCRX) in Q4 2024, closing a stake of 34,200 shares — an estimated $515K sold.

Caxton Associates (New York) first reported a position in PCRX in Q2 2020 and held it in 2 quarters. The position peaked at $515K in Q3 2024. 233 funds tracked by Wall St. Rank hold PCRX as of Q4 2024.

  • Caxton Associates (New York) reported no remaining Pacira BioSciences position as of Q4 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 34,200 Pacira BioSciences shares in Q4 2024, an estimated $515K.
  • Caxton Associates (New York) first reported a position in Pacira BioSciences in Q2 2020 and held it in 2 quarters.
  • Caxton Associates (New York)'s Pacira BioSciences position peaked at $515K in Q3 2024.
  • 233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.